Summary:
- The U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" status to Neuralink's vision-restoring implant called "Blindsight."
- The Blindsight implant is designed to restore some level of vision in people who have lost their sight due to certain types of retinal diseases or injuries.
- The Breakthrough Device designation from the FDA will expedite the development and review process for the Blindsight implant, potentially allowing it to reach the market faster and provide a new treatment option for those with vision loss.